



Date: February 17, 2026
From: Katie Szyman
To: Masimo Partners
Subj: Acquisition of Masimo

Dear Masimo Partners,

Today we announced that we've reached an agreement to be acquired by Danaher.

As you may know, Danaher is a global science and technology innovator comprised of a set of businesses across biotechnology, diagnostics, and life sciences. Joining Danaher will accelerate our ability to fulfill our mission of delivering innovations that empower clinicians to transform patient care.

Following the transaction, Masimo will operate as a standalone business unit within Danaher's Diagnostics segment and strengthen Danaher's offering in acute care settings.

For the time being, there will be no changes in our operations or your day-to-day interactions with our team, and we expect a smooth transition post-closing. Your contacts at Masimo remain the same. Our chief priority remains being great partners to you and our customers.

As with any transaction, the closing is subject to the satisfaction or waiver of certain closing conditions, including the receipt of required regulatory approvals. It is expected to close in the second half of 2026.

If you have any questions, please do not hesitate to reach out to your regular point of contact at Masimo.

Sincerely,

Katie